← Back to all trials
Available
NCT04159597
Expanded Access to Upadacitinib
Conditions: Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Non-radiographic Axial, Spondyloarthritis, Giant Cell Arteritis, Systemic Lupus Erythematosus, Alopecia Areata, Non Segmental Vitiligo, Hidradenitis Suppurativa
Sex: All
Healthy volunteers: No
Sponsor: AbbVie
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Eligibility Criteria
Exclusion Criteria:
* There are other suitable treatment options.
* The participant qualifies for ongoing clinical trials.
Source: ClinicalTrials.gov (NCT04159597). StuddyBuddy aggregates publicly available trial information.
